13F-HR filed by Aisling Capital Management LP
Aisling Capital Management LP filed this 13F-HR for the quarter ended 2021-09-30, filed 2021-11-12, with 21 holding rows worth $501,479,000.
- Accession
- 0001766721-21-000006
- Filer
- CIK 1766721
- Filed
- 2021-11-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2021
A holdings report, 21 entries on the cover page, a total value of $501,479,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $501,479,000 with VALUE read as thousands by filing date, 13F file number 028-19070. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 6,068,125 | $284,413,000 | thousands by filing date | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 1,472,331 | $32,804,000 | thousands by filing date | |
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 2,541,009 | $25,258,000 | thousands by filing date | |
| HARMONY BIOSCIENCES HLDGS IN | 413197104 | COM | 592,815 | $22,723,000 | thousands by filing date | |
| ELEVATION ONCOLOGY INC COM | 28623U101 | Stock | 2,834,910 | $22,084,000 | thousands by filing date | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 1,025,000 | $19,588,000 | thousands by filing date | |
| AEGLEA BIOTHERAPEUTICS INC | 00773J103 | COM | 1,691,151 | $13,445,000 | thousands by filing date | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 634,455 | $11,420,000 | thousands by filing date | |
| BIOMEA FUSION INC | 09077A106 | CMN | 798,757 | $9,561,000 | thousands by filing date | |
| TALARIS THERAPEUTICS INC | 87410C104 | COM | 682,923 | $9,260,000 | thousands by filing date | |
| POSEIDA THERAPEUTICS INC | 73730P108 | COM | 1,043,267 | $7,605,000 | thousands by filing date | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 1,332,485 | $7,302,000 | thousands by filing date | |
| SPRUCE BIOSCIENCES INC | 85209E109 | COM | 1,205,511 | $7,245,000 | thousands by filing date | |
| RENEO PHARMACEUTICALS INC | 75974E103 | COM | 886,075 | $6,601,000 | thousands by filing date | |
| TECTONIC THERAPEUTIC INC COM | 05455M100 | Stock | 1,009,779 | $5,635,000 | thousands by filing date | |
| MARKER THERAPEUTICS INC | 57055L107 | COM | 3,142,857 | $5,311,000 | thousands by filing date | |
| ObsEva SA | H5861P103 | COM | 1,386,338 | $4,312,000 | thousands by filing date | |
| ATRECA INC | 04965G109 | COM | 387,653 | $2,415,000 | thousands by filing date | |
| VIRACTA THERAPEUTICS INC | 92765F108 | COM | 288,571 | $2,314,000 | thousands by filing date | |
| ZOSANO PHARMA CORP | 98979H202 | COM NEW | 2,718,226 | $1,956,000 | thousands by filing date | |
| NABRIVA THERAPEUTICS PLC | G63637113 | SHS | 191,028 | $227,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001766721-21-000006 | this filing | 2021-11-12 | acceptance time not in the bulk data set |